Gilead Sciences | GILD - Zysk Brutto Na Sprzedaży





Zysk Brutto Na Sprzedaży Zmiana Data
AbbVie USD 12.54B 474M 2026-03
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
ALKERMES USD 331.33M 7M 2026-03
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Amgen USD 6.89B 415M 2025-12
Biogen USD 1.82B 169.5M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Coherus Biosciences USD 8.7M 853K 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Gilead Sciences USD 5.52B 791M 2026-03
GlaxoSmithKline GBP 5.75B 429M 2026-03
Glaxosmithkline GBP 8.75B 2.92B 2025-09
Incyte USD 1.17B 217.51M 2026-03
J&J USD 17.24B 642M 2026-03
Merck USD 10.85B 2.57B 2025-12
Moderna USD -566M 792M 2026-03
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novartis USD 10.07B 184M 2026-03
Pfizer USD 11.04B 1.24B 2026-03
PTC Therapeutics USD 232.94M 84.56M 2026-03
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.45B 1.31B 2025-12
Sarepta Therapeutics USD 621.34M 577.79M 2026-03
United Therapeutics USD 315.5M 286.6M 2025-12
Vertex Pharmaceuticals USD 2.6B 121.7M 2026-03